Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sophocarpidine in preparation of medicine for treating bacterial vaginosis

A technology of matrine total alkaloids and bacteria, which is applied in the field of matrine total alkaloids in the preparation of drugs for the treatment of bacterial vaginosis, which can solve the adverse effects of difficult inactivation, the inability of the human host immune system to effectively remove pathogens, and healthy vaginal microecology To achieve the effect of improving the cure rate and reducing the recurrence rate

Inactive Publication Date: 2020-11-13
GUIYANG XINTIAN PHARMA CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After the bacteria form a biofilm, because the dense intercellular matrix encloses the bacteria, the human host’s immune system cannot effectively remove the pathogen, and it is difficult for antibiotics to completely inactivate it. The bacteria show stronger drug resistance and are easy to form Persistent infection, and the gradual emergence of drug-resistant strains also have adverse effects on the healthy vaginal microecology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sophocarpidine in preparation of medicine for treating bacterial vaginosis
  • Application of sophocarpidine in preparation of medicine for treating bacterial vaginosis
  • Application of sophocarpidine in preparation of medicine for treating bacterial vaginosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Isolation, purification and identification of anaerobic bacteria from vaginal secretions of BV patients

[0025] (1) Criteria for the study population

[0026] Inclusion criteria: ① Bacterial vaginosis patients with Nugent score ≥ 7 and clinical symptoms; ② Age: 18-50 years old; ③ Can complete standard treatment; ④ Informed consent.

[0027] Exclusion criteria: ①Women during pregnancy, lactation and menopause; ②Those who take hormone drugs for a long time due to other diseases; ③Those who take immunosuppressants; ④Those who have heart, liver, kidney, endocrine and other medical diseases (mainly through consultation) ; ⑤ people with trichomonas, vulvovaginal candidiasis and other vaginal infections; ⑥ people allergic to metronidazole; ⑦ people with poor compliance.

[0028] (2) Number of enrolled cases

[0029] 100 patients with BV.

[0030] (3) Isolation, purification and storage of clinical Gardnerella strains

[0031] 1) Put the casman agar plate coate...

Embodiment 2

[0042] Example 2 Sophora flavescens preparation, metronidazole drug susceptibility test to Gardnerella clinical isolates

[0043] The MIC was determined by the microbroth dilution method in the CLSI (Clinical & Laboratory Standards Institute:) Guideline for Drug Susceptibility of Anaerobic Bacteria, and the standard strain of Bacteroides fragilis (ATCC 25285) was selected as the quality control bacteria.

[0044] (1) Preparation of antimicrobial drug dilution: thaw the pre-prepared antimicrobial drug stock solution or freshly prepared on the day of the test, and fill the test tube with quantitative sterilized distilled water or buffer solution as the blank solution of the dilution solution. Dilution preparation method: Use 1:2, 1:4 and 1:8 serial dilution methods to prepare the intermediate solution of antibacterial drugs (10×final concentration), and prepare the dilution according to this method to reduce dilution errors.

[0045]The final concentrations of the total alkalo...

Embodiment 3

[0065] Example 3 Total alkaloids of Sophora flavescens inhibits Gardnerella biofilm

[0066] (1) Detection of minimum biofilm inhibitory concentration (MBIC) of total alkaloids of matrine on Gardnerella

[0067] 1) Bacterial liquid preparation: Take 10 μL of isolated and purified strains frozen in a -80°C refrigerator and inoculate them on casman solid medium, in 5% CO 2 , 37 ℃ static culture. After 48 hours of culture, pick a single colony and use a McFarland turbidimeter to prepare a bacterial solution of 0.5 McFarland units for use.

[0068] 2) Biofilm culture: 0.5 McFarland bacteria suspension (about 1.5×10 8 CFU / mL) was diluted 1:3 to reach 5×10 7 CFU / mL, add the diluted bacterial suspension to the prepared micro-dilution plate, add 10 μL to each well, so that the final concentration of bacteria is about 5×10 6 CFU / mL (in order to make the biofilm form better, increase the initial inoculum amount to 5 times that of the MIC experiment), put the inoculated micro-dilut...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of sophocarpidine in preparation of a medicine for treating bacterial vaginosis. The pathogenic bacteria of the bacterial vaginosis (BV) comprise gardnerella vaginalis, prawn bacteria, atorbacter vaginalis, mycoplasma hominis, campylobacter mobilis, and drug-resistant bacteria and a biological membrane of the pathogenic bacteria, and the drug takes sophocarpidine as an active ingredient and inhibits or kills the pathogenic bacteria and the drug-resistant bacteria and the biological membrane of the pathogenic bacteria. According to the invention, the matrinecan effectively inhibit gardnerella vaginalis; the obvious inhibiting and killing effects are also achieved on metronidazole drug-resistant strains; the formation of a biological membrane structure ofthe gardnerella vaginalis can be effectively inhibited; it is proved that the sophocarpidine has the effect of inhibiting main pathogenic bacteria of BV and biological membranes of the main pathogenic bacteria and has antibacterial drug resistance, and therefore when the sophocarpidine or products of the sophocarpidine are used for BV patients, the cure rate can be effectively increased, the recurrence rate and antibiotic drug resistance can be effectively reduced, and a new treatment choice is provided for clinical BV patients.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the use of matrine total alkaloids in the preparation of medicines for treating bacterial vaginosis. Background technique [0002] Bacterial vaginosis (Bacterial Vaginosis, BV) is an overgrowth of anaerobic microorganisms in the vagina (such as Gardnerella vaginalis (Gardnerella Vaginalis, GV), Prevotella, Atobobacter, Mycoplasma hominis, Campylobacter, etc.), replacing Lactobacillus as the dominant bacterium, leading to a vaginal flora disorder characterized by an increase in the pH value of the vagina. The disease can lead to adverse pregnancy outcomes, such as spontaneous abortion, premature delivery, amniotic fluid infection, postpartum endometritis, and cesarean section infection and perinatal complications. Regarding the pathogenesis of BV, the new European guidelines in 2018 pointed out that the formation of Gardnerella vaginalis biofilm is an important factor leadi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/489A61K31/4375A61P15/02A61P31/04
CPCA61K36/489A61K31/4375A61P15/02A61P31/04
Inventor 董大伦
Owner GUIYANG XINTIAN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com